<DOC>
	<DOCNO>NCT02947711</DOCNO>
	<brief_summary>This Phase 1 , open-label , single-sequence , drug-drug Interaction study conduct evaluate effect diltiazem extend release ( ER ) ( moderate CYP3A inhibitor P glycoprotein [ Pgp ] inhibitor ) pharmacokinetics ( PK ) single oral dose E2027 healthy participant .</brief_summary>
	<brief_title>Study Evaluate Effect Diltiazem Extended Release Pharmacokinetics E2027 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diltiazem</mesh_term>
	<criteria>Nonsmoking , male female participant , ≥18 year old ≤50 year old time inform consent Body mass index 18 32 kilogram per meter square ( kg/m^2 ) Screening Clinically significant illness require medical treatment within 8 week clinically significant infection require medical treatment within 4 week prior first dose Females : ( ) breastfeeding ; ( b ) pregnant Screening Baseline ( document negative beta human chorionic gonadotropin [ βhCG ] ( human chorionic gonadotropin [ hCG ] ) test sensitivity least 25 International Units per Liter ( IU/L ) equivalent unit βhCG [ hCG ] ) . Note : A negative urine pregnancy test require administration first dose . Females childbearing potential : Had unprotected sexual intercourse within 30 day study entry agree use highly effective method contraception ( e.g. , total abstinence , intrauterine device , double barrier method [ condom plus diaphragm spermicide ] vasectomize partner confirm azoospermia ) throughout entire study period 28 day study drug discontinuation . Note : Hormonal contraceptive allow . Are currently ( least 30 day ) abstinent , agree use double barrier method ( describe ) refrain sexual activity study period 28 day study drug discontinuation NOTE : All female consider childbearing potential unless postmenopausal ( amenorrheic least 12 consecutive month , appropriate age group , without know suspected cause ) sterilize surgically ( i.e. , bilateral tubal ligation , hysterectomy , bilateral oophorectomy , surgery least 1 month prior first dose ) . Males successful vasectomy ( confirm azoospermia ) female partner meet criterion ( i.e. , childbearing potential practicing highly effective contraception throughout study period 28 day study drug discontinuation ) . No sperm donation allow study period 28 day study drug discontinuation . Evidence disease may influence outcome study within 4 week prior first dose ( e.g. , psychiatric disorder disorder gastrointestinal tract , liver , kidney , respiratory system , endocrine system , hematological system , neurological system , cardiovascular system , participant congenital abnormality metabolism ) Any history abdominal surgery may affect pharmacokinetic profile E2027 ( e.g. , hepatectomy , nephrectomy , digestive organ resection ) . Participants history cholecystectomy appendectomy exclude . Any clinically abnormal symptom organ impairment find medical history , physical examination , vital sign , electrocardiogram ( ECG ) finding ( include PR great 210 millisecond ( msec ) , QRS great 110 msec ) , laboratory test result require medical treatment Screening Baseline determine Principal Investigator designee A prolonged QT/QTc interval ( QTc great 450 msec ) demonstrate ECG Screening Baseline ( base average triplicate ECGs ) . A history risk factor torsade de pointes ( e.g. , heart failure , hypokalemia , family history long QT Syndrome ) use concomitant medication prolong QT/QTc interval Left bundle branch block Screening Baseline Persistent systolic blood pressure ( BP ) great 160 less 100 millimeter mercury ( mmHg ) diastolic BP great 100 less 50 mmHg Screening Baseline Persistent pulse rate le 50 beats/minute ( min ) 90 beats/min Screening Baseline History myocardial infarction , ischemic heart disease , cardiac failure Screening History clinically significant arrhythmia uncontrolled arrhythmia Known history clinically significant drug allergy Screening Baseline Participants contraindication diltiazem Extended Release Known history food allergy presently experience significant seasonal perennial allergy Screening Baseline Known human immunodeficiency virus ( HIV ) positive Screening Active viral hepatitis ( A , B , C ) demonstrate positive serology Screening History drug alcohol dependency abuse within 2 year Screening , positive urine drug alcohol test Screening Baseline Participants smoke use tobacco nicotinecontaining product within 4 week prior first dose A Columbia Suicide Severity Rating Scale ( CSSRS ) suicidal ideation score 4 5 Screening Baseline , period within 6 month Screening Baseline , lifetime suicidal behavior Currently enrol another clinical trial use investigational drug device within 30 day ( 5 halflives , whichever long ) precede inform consent Engagement strenuous exercise within 2 week prior first dose ( e.g. , marathon runner , weight lifter ) Intake caffeinated beverage caffeinated food within 72 hour prior first dose Intake nutritional supplement , juice , herbal preparation food beverage may affect various drug metabolize enzyme transporter ( e.g. , alcohol , grapefruit , grapefruit juice , grapefruitcontaining beverage , apple orange juice , vegetables mustard green family [ e.g. , kale , broccoli , watercress , collard green , kohlrabi , Brussels sprout , mustard ] , charbroiled meat ) within 1 week prior first dose Intake herbal preparation contain St. John 's Wort within 4 week prior first dose Intake overthecounter ( OTC ) medication within 14 day ( 5 halflives , whichever long ) dose unless Principal Investigator sponsor medical monitor consider compromise participant safety study assessment Use prescription drug within 4 week prior first dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>E2027</keyword>
	<keyword>Healthy participant</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>